I-mab Biopharma US Limited

I-mab

I-mab Biopharma (hangzhou) Co., Ltd.

I-mab Biopharma Co., Ltd.

Abl Bio Inc.

Bingshi Guo

Lei Fang

Zhengyi Wang

Jingwu Zang

Yongqiang Wang

Wenqing Jiang

Feifei Cui

Eunyoung Park

Eunsil Sung

Byungje Sung

Qiumei Yang

Yuanyuan Yang

Haijuan Gu

The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.

CD47 monoclonal antibodies and uses thereof

Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also provided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders.

Anti-GM-CSF antibodies and uses thereof

Provided are anti-CD73 antibodies or fragments thereof. The antibodies or fragments therefore include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. More generally, antibodies or fragments thereof are described which have specificity to one or more amino acid residues selected from the C-terminal half of a human CD73 protein, such as those in the C-terminal domains. Specific epitope amino acids in these domains include Y345, D399, E400, R401 and R480. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer are also provided.

Anti-CD73 antibodies and uses thereof

The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.

Anti-LAG-3 antibodies and uses thereof

Provided are fusion molecule having a PD-L1 inhibitor fused to a human IL-7 protein or fragment thereof through a peptide linker. The disclosed fusion molecules exhibited synergistic anti-tumor effects.

Anti-PD-L1 antibody and IL-7 fusions

Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof

Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 116, a VH CDR3 of SEQ ID NO: 117, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

Anti-PD-L1 antibodies and uses thereof

Provided are full human anti-PD-L1 antibodies or fragments thereof. In various examples, the antibodies or fragments thereof include a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3 which are selected from sequence groups of SEQ ID NO: 35-42, SEQ ID NO: 43-51, SEQ ID NO: 52-66, SEQ ID NO: 67-79, SEQ ID NO:80-88 and SEQ ID NO: 89-102, respectively, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

Human PD-L1 antibodies

Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific antibodies are effective in treating cancer.

Anti-CD73 anti-PD-L1 bispecific antibodies

The present disclosure provides antibodies and fragments thereof having specificity to a human T cell immunoreceptor with Ig and ITIM domains (TIGIT) protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and viral infections are also provided.

Antibodies to T cell immunoreceptor with IG and ITIM domains (TIGIT) and uses thereof

Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

Growing community of inventors

Shanghai, China

Bingshi Guo